When is being in a hurry going too fast? Lessons learned from clinical trials in cervical cancer

Gynecologic Oncology

Volumn 113, Issue 1, 2009, Pages 1-3

  Monk, Bradley J ^a   Ali, Shamshad ^b   Gaffney, David K ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RADIOSENSITIZING AGENT; TIRAPAZAMINE; TOPOTECAN;

ANEMIA; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; GRANULOCYTOPENIA; HUMAN; HYDRONEPHROSIS; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEUKOPENIA; METABOLIC DISORDER; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; UTERINE CERVICAL NEOPLASMS;

EID: 62749112841     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.02.015     Document Type: Editorial

References (22)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J. Clin. 55 2 (2005) 74-108
2. http://www.gcig.igcs.org/.
3. Monk B.J., Sill M.W., Burger R.A., Gray H.J., Buekers T.E., and Roman L.D. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J. Clin. Oncol. (2009 Jan 12) [electronic publication ahead of print]
4. Rose P.G., et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: A Gynecologic Oncology Group study. J. Clin. Oncol. 25 19 (2007) 2804-2810
5. Bonner J.A., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 6 (2006) 567-578
6. Gaffney D.K., Winter K., Dicker A.P., Miller B., Eifel P.J., Ryu J., et al. A phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: Primary endpoint analysis of RTOG 0128. Int. J. Radiat. Oncol. Biol. Phys. 67 1 (2007 Jan 1) 104-109
7. Gaffney D.K., Winter K., Dicker A.P., Miller B., Eifel P.J., Ryu J., et al. Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int. J. Radiat. Oncol. Biol. Phys. 69 1 (2007 Sep 1) 111-117
8. ClinicalTrials.gov Identifier: NCT00369122.
9. DiSilvestro P.A., Walker J.L., Morrison A., Rose P.G., Homesley H., and Warshal D. Gynecologic Oncology Group. Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: A phase I/II study of the Gynecologic Oncology Group. Gynecol. Oncol. 103 3 (2006 Dec) 1038-1042 GOG 0219
10. ClinicalTrials.gov Identifier: NCT00704873.
11. Craighead P.S., Pearcey R., and Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 48 3 (2000 Oct 1) 791-795
12. ClinicalTrials.gov Identifier: NCT00104910.
13. Monk B.J., Sill M., McMeekin D.S., Cohn D.E., Ramondetta L., Boardman C.H., et al. A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a gynecologic oncology group (GOG) study. J. Clin. Oncol. 26 (2008) (May 20 suppl; abstr LBA5504)
14. GOG 0240 (personal communication Krishnansu S. Tewari PI).
15. Tiersten A.D., Selleck M.J., Hershman D.L., Smith D., Resnik E.E., Troxel A.B., et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol. Oncol. 92 (2004) 635-638
16. West W., Birch R., Schnell F., Hainsworth J., Tongol J., and Campos L. Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. Oncology 8 (2003) 76-82
17. Stathopoulos G.P., Rigatos S.K., Christodoulou C., Malamos N.A., Deliyiannis F., Stathopoulos J.G., et al. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: A phase I/II study. Cancer Chemother. Pharmacol. 54 (2004) 259-264
18. Stathopoulos G.P., Malamos N.A., Aravantinos G., Rigatos S., Christodoulou C., Stathopoulos J., et al. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer Chemother. Pharmacol. 60 (2007) 123-126
19. Homesley H.D., Benigno B., Williams J., and Vaccarello L. A phase I study of weekly topotecan and paclitaxel in previously treated ovarian carcinoma patients. Gynecol. Oncol. 87 (2002) 171-177
20. Kurtz et al.
21. Long III H.J., Bundy B.N., Grendys Jr. E.C., Benda J.A., McMeekin D.S., Sorosky J., et al. Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J. Clin. Oncol. 23 21 (2005 Jul 20) 4626-4633
22. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360 (2009) 563-572